Initial combination of metformin, sitagliptin, and empagliflozin in drug-naïve patients with type 2 diabetes: Safety and metabolic effects.

, , ,

제1저자 임수 · 교신저자 Ferrannini E

PMID 34908220 DOI 10.1111/dom.14627 IF 6.1 내분비대사내과

소속 (2)

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea.
CNR Institute of Clinical Physiology, Pisa, Italy.

Keywords

SGLT2 inhibitordrug mechanismtype 2 diabetes

그 밖의 정보

출판 형태: Letter, Research Support, Non-U.S. Gov't
저널: Diabetes, obesity & metabolism · eISSN 1463-1326
전자 출판: 2022-01-02
MeSH: Benzhydryl Compounds / adverse effects · Diabetes Mellitus, Type 2* / metabolism · Drug Therapy, Combination · Glucosides / adverse effects · Glycated Hemoglobin / metabolism · Humans · Hypoglycemic Agents / adverse effects · Metformin* / adverse effects · Sitagliptin Phosphate / adverse effects · Treatment Outcome
Substances: Benzhydryl Compounds · Glucosides · Glycated Hemoglobin · Hypoglycemic Agents · Metformin · Sitagliptin Phosphate · empagliflozin
참고문헌: 21편